FierceBiotech23h
Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Vertex Pharmaceuticals, Orna Therapeutics announce research collaboration
Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
This was the stock's third consecutive day of gains.
Nasdaq12d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Benzinga.com1mon
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts
In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals VRTX, offering a diverse range of perspectives from bullish to bearish. The following table encapsulates ...